Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alexion Pharm Inc (ALXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,043,782
  • Shares Outstanding, K 223,410
  • Annual Sales, $ 3,084 M
  • Annual Income, $ 399,000 K
  • 36-Month Beta 1.18
  • Price/Sales 7.91
  • Price/Cash Flow 20.04
  • Price/Book 3.01

Price Performance

See More
Period Period Low Period High Performance
1-Month
118.00 +4.81%
on 01/08/18
126.29 -2.07%
on 01/03/18
+4.89 (+4.12%)
since 12/22/17
3-Month
105.01 +17.77%
on 12/07/17
142.24 -13.06%
on 10/24/17
-15.35 (-11.04%)
since 10/20/17
52-Week
96.18 +28.58%
on 05/26/17
149.34 -17.19%
on 09/05/17
-8.30 (-6.29%)
since 01/20/17

Most Recent Stories

More News
What's in the Cards for Varian Medical (VAR) in Q1 Earnings?

Varian Medical's (VAR) lackluster performance in Halcyon platform and disappointing financials are likely to dampen results in Q1.

AGIO : 78.35 (+12.10%)
VAR : 110.02 (-0.27%)
ABBV : 106.49 (+1.77%)
ALXN : 123.67 (+2.16%)
What's in the Cards for Biogen (BIIB) This Earnings Season?

On the Q4 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise, and Spinraza's performance.

EBS : 50.41 (-1.52%)
RHHBY : 30.7900 (+0.33%)
ALXN : 123.67 (+2.16%)
BIIB : 347.64 (+1.53%)
Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season?

Here is a look at four large-cap pharma and biotech stocks including Merck (MRK) that could surpass earnings expectations in the fourth quarter.

CELG : 102.91 (+0.25%)
MRK : 61.25 (-0.05%)
ABBV : 106.49 (+1.77%)
JUNO : 86.00 (+26.82%)
SNY : 43.20 (-3.14%)
ALXN : 123.67 (+2.16%)
BIIB : 347.64 (+1.53%)
Alexion to Report Fourth Quarter and Full Year 2017 Results on Thursday, February 8, 2018

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2017 on Thursday, February...

ALXN : 123.67 (+2.16%)
The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex

The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex

CELG : 102.91 (+0.25%)
VRTX : 161.91 (+2.49%)
EXEL : 29.44 (+5.14%)
AMGN : 192.33 (+1.61%)
ALXN : 123.67 (+2.16%)
Azzur New England Introduces New Director of Engineering Services

Azzur Group is pleased to announce that Robert Reddick has joined the company as Director of Engineering Services for the New England office. Rob comes to Azzur from Alexion Pharmaceuticals, where he...

ALXN : 123.67 (+2.16%)
Can Biotech Keep Last Year's Momentum Alive in 2018?

The biotech sector performed impressively in 2017 and the momentum is expected to continue in 2018 driven by new drug approvals. Acquisitions will also remain in focus.

CELG : 102.91 (+0.25%)
VRTX : 161.91 (+2.49%)
EXEL : 29.44 (+5.14%)
GILD : 81.41 (+0.53%)
REGN : 375.86 (+1.17%)
AMGN : 192.33 (+1.61%)
ALXN : 123.67 (+2.16%)
Omeros Inks Agreement With FDA for OMS721 Phase III Trial

Omeros (OMER) inks an agreement with the FDA on Omeros' protocol for a phase III study to evaluate its lead pipeline candidate, OMS721, for treatment of patients with IgA nephropathy.

SCMP : 17.90 (-0.28%)
ACRX : 2.00 (-2.44%)
OMER : 17.18 (+2.87%)
ALXN : 123.67 (+2.16%)
Will These 2 Large-Cap Biotechs Be on Investor Radar in '18?

Both Vertex and Alexion enjoy dominant positions in medical areas - cystic fibrosis (CF) for Vertex and ultra-rare disorders for Alexion - that are not very competitive.

VRTX : 161.91 (+2.49%)
ALXN : 123.67 (+2.16%)
Alexion and Elliott Agree to Collaborate on Identifying a New Board Member

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) said today that its Board of Directors and Elliott have agreed to work collaboratively to promptly identify a new member to join the Alexion Board....

ALXN : 123.67 (+2.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Alexion Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved...

See More

Key Turning Points

2nd Resistance Point 126.20
1st Resistance Point 124.94
Last Price 123.67
1st Support Level 121.50
2nd Support Level 119.32

See More

52-Week High 149.34
Fibonacci 61.8% 129.03
Last Price 123.67
Fibonacci 50% 122.76
Fibonacci 38.2% 116.49
52-Week Low 96.18

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.